Anti-Human TNFa/TNF-alpha Antibody (SAA2506) from ProteoGenix; catalogue ARO-A22950; research use only.
Know who made it. See the evidence. Buy through one marketplace.
SAA2506, the powerful Anti-Human TNFa/TNF-alpha Antibody designed for cutting-edge biotech research. This highly specific and potent antibody targets the tumor necrosis factor alpha (TNFa/TNF-alpha) protein, a key player in inflammatory and immune responses.
With its ability to bind and neutralize TNFa/TNF-alpha, SAA2506 has a wide range of applications in both basic and clinical research. It has been extensively validated for use in ELISA, Western blot, immunohistochemistry, and flow cytometry, making it a versatile tool for studying TNFa/TNF-alpha in various biological samples.
SAA2506 has been shown to effectively block the activity of TNFa/TNF-alpha, making it an essential tool for investigating the role of this cytokine in diseases such as rheumatoid arthritis, inflammatory bowel disease, and cancer. Its high specificity and potency ensure reliable and reproducible results, making it a top choice for researchers looking to advance their understanding of TNFa/TNF-alpha.
In addition to its use in basic research, SAA2506 has also shown promising results in clinical trials as a potential therapeutic agent for TNFa/TNF-alpha-related diseases. Its ability to target and neutralize TNFa/TNF-alpha makes it a promising candidate for the development of new treatments for inflammatory and immune-mediated disorders.
In summary, SAA2506 is a highly effective and specific Anti-Human TNFa/TNF-alpha Antibody that has been extensively validated for use in a variety of research applications. With its potential to advance our understanding of TNFa/TNF-alpha and its potential as a therapeutic agent, SAA2506 is a valuable tool for any biotech research targeting this important cytokine. Order now and take your research to the next level with SAA2506.
ProteoGenix catalogue number ARO-A22950. For research use only.
Target: C-domain 1, C-domain 2, Cachectin, ICD1, ICD2, Intracellular domain 1, Intracellular domain 2, N-terminal fragment, NTF, TNF, TNF-a, TNF-alpha, TNFA, TNFSF2, Tumor necrosis factor, Tumor necrosis factor ligand superfamily member 2, Tumor necrosis factor, membrane form, Tumor necrosis factor, soluble form; Clonality: Monoclonal Antibody; Reactivity: Human; Applications: ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Species | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Human |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
